The terms, per the grant. On October 13, 2020, Merck Sharp & Dohme was issued US10800826B2, "Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors." The CPC stack — C07K 14/605, A61K 47/6811 and A61K 47/6843 (peptide-to-antibody conjugation), plus C07K 16/26 — describes a half-life-extension play: bolt an incretin peptide onto an antibody scaffold to make it last.
Why the structure matters to a deal desk: in metabolic medicine, durability is the franchise. A conjugate that fuses a dual agonist to an antibody is an engineering answer to the dosing-frequency problem, and engineering answers that are patented are the assets that get licensed. The conjugation chemistry, not just the peptide, is the protectable value here.
The disciplined read: separate the molecule from the delivery. This grant claims a way of presenting a dual agonist, which can be licensed independently of any single clinical candidate. For a model, that means the asset's value is partly platform — applicable across peptides — and partly program-specific. Naming the grant is how you avoid pricing the press release.
What the grant does not promise: a marketed product, a best-in-class profile, or freedom from the broader incretin IP thicket. A conjugate grant is an exclusivity claim on a construction method, not a clinical result. Those live in separate filings.
The takeaway: when valuing a metabolic deal, read the conjugation and half-life claims as carefully as the peptide claims. Merck's October 2020 grant is a dated, issued example of the dual-agonism-plus-durability bet that the whole sector has since chased.